OPZELURA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Opzelura, and what generic alternatives are available?
Opzelura is a drug marketed by Incyte Corp and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.
This drug has three hundred and twenty-four patent family members in forty-eight countries.
The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Opzelura
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 12, 2028. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for OPZELURA
| International Patents: | 324 |
| US Patents: | 17 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 65 |
| Clinical Trials: | 2 |
| Patent Applications: | 514 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for OPZELURA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OPZELURA |
| What excipients (inactive ingredients) are in OPZELURA? | OPZELURA excipients list |
| DailyMed Link: | OPZELURA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OPZELURA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OPZELURA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Incyte Corporation | Phase 3 |
| Incyte Corporation | Phase 2 |
Pharmacology for OPZELURA
| Drug Class | Janus Kinase Inhibitor Kinase Inhibitor |
| Mechanism of Action | Janus Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for OPZELURA
Paragraph IV (Patent) Challenges for OPZELURA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| OPZELURA | Cream | ruxolitinib phosphate | 1.5% | 215309 | 1 | 2023-07-31 |
US Patents and Regulatory Information for OPZELURA
OPZELURA is protected by eighteen US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of OPZELURA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting OPZELURA
Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical formulation for a JAK inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical formulation for a JAK inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical formulation for a JAK inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Ruxolitinib formulation for reduction of itch in atopic dermatitis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF LASER OR PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting OPZELURA
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OPZELURA
When does loss-of-exclusivity occur for OPZELURA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08266183
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0814254
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 89663
Estimated Expiration: ⤷ Sign Up
China
Patent: 1932582
Estimated Expiration: ⤷ Sign Up
Patent: 3524509
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 51256
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 151
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0140541
Estimated Expiration: ⤷ Sign Up
Patent: 0160717
Estimated Expiration: ⤷ Sign Up
Patent: 0190385
Estimated Expiration: ⤷ Sign Up
Cuba
Patent: 933
Estimated Expiration: ⤷ Sign Up
Patent: 179
Estimated Expiration: ⤷ Sign Up
Patent: 090213
Estimated Expiration: ⤷ Sign Up
Patent: 120155
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 15145
Estimated Expiration: ⤷ Sign Up
Patent: 17693
Estimated Expiration: ⤷ Sign Up
Patent: 21338
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 73752
Estimated Expiration: ⤷ Sign Up
Patent: 40731
Estimated Expiration: ⤷ Sign Up
Patent: 70090
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 009000280
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 099802
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 9784
Estimated Expiration: ⤷ Sign Up
Patent: 1070013
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 73752
Estimated Expiration: ⤷ Sign Up
Patent: 40731
Estimated Expiration: ⤷ Sign Up
Patent: 70090
Estimated Expiration: ⤷ Sign Up
Patent: 95369
Estimated Expiration: ⤷ Sign Up
Patent: 11883
Estimated Expiration: ⤷ Sign Up
Georgia, Republic of
Patent: 0125533
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 0900314
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 43161
Estimated Expiration: ⤷ Sign Up
Patent: 98652
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 29236
Estimated Expiration: ⤷ Sign Up
Patent: 43732
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2524
Estimated Expiration: ⤷ Sign Up
Patent: 4276
Estimated Expiration: ⤷ Sign Up
Patent: 0401
Estimated Expiration: ⤷ Sign Up
Patent: 7708
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 75653
Estimated Expiration: ⤷ Sign Up
Patent: 10529209
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 70090
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 4969
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 2814
Estimated Expiration: ⤷ Sign Up
Patent: 09013402
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 960
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 517
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1803
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 0900216
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 19025
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 73752
Estimated Expiration: ⤷ Sign Up
Patent: 40731
Estimated Expiration: ⤷ Sign Up
Patent: 70090
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 73752
Estimated Expiration: ⤷ Sign Up
Patent: 70090
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 201000002
Estimated Expiration: ⤷ Sign Up
Patent: 01000002
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 245
Estimated Expiration: ⤷ Sign Up
Patent: 878
Estimated Expiration: ⤷ Sign Up
Patent: 449
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 2198
Estimated Expiration: ⤷ Sign Up
Patent: 201509887U
Estimated Expiration: ⤷ Sign Up
Patent: 201912675V
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 73752
Estimated Expiration: ⤷ Sign Up
Patent: 40731
Estimated Expiration: ⤷ Sign Up
Patent: 70090
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0908826
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1549876
Estimated Expiration: ⤷ Sign Up
Patent: 100049010
Estimated Expiration: ⤷ Sign Up
Patent: 150036210
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 67665
Estimated Expiration: ⤷ Sign Up
Patent: 75797
Estimated Expiration: ⤷ Sign Up
Patent: 14092
Estimated Expiration: ⤷ Sign Up
Patent: 03444
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 09000514
Estimated Expiration: ⤷ Sign Up
Turkey
Patent: 1903488
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 467
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering OPZELURA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2611588 | ⤷ Sign Up | |
| South Africa | 200908826 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTHYLPROPANEITRILE | ⤷ Sign Up |
| Lithuania | 2426129 | ⤷ Sign Up | |
| Croatia | P20170200 | ⤷ Sign Up | |
| Taiwan | 201240663 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | ⤷ Sign Up |
| Israel | 223084 | תכשיר לשימוש מקומי למעכב jak (Topical formulation for a jak inhibitor) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPZELURA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1966202 | 2013C/014 | Belgium | ⤷ Sign Up | PRODUCT NAME: RUXOLITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828 |
| 2455382 | LUC00016 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: RUXOLITINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001-016 20150313 |
| 1966202 | 2013/004 | Ireland | ⤷ Sign Up | PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823 |
| 1966202 | 92137 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: RUXOLITINIB,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES |
| 1966202 | CR 2013 00005 | Denmark | ⤷ Sign Up | PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823 |
| 1966202 | 448 | Finland | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
